Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 3 of 3
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial
    (Elsevier BV, 2025-11)
    Batmunkh, Tsetsegsaikhan
    ;
    Neal, Eleanor F G
    ;
    Amraa, Otgonjargal
    ;
    Mazarakis, Nadia
    ;
    Altangerel, Bolor
    BACKGROUND: COVID-19 vaccine booster doses counteract waning immunity and vaccine escape by emerging variants. We evaluated long-term immunogenicity and safety of fractional and standard BNT162b2 vaccine booster doses in Mongolia. METHODS: In this randomised, controlled, non-inferiority trial, adults primed with two doses of ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were randomised (1:1) to receive a 15 μg (fractional dose) or 30 μg (standard dose) BNT162b2 booster. Geometric mean ratios (GMR) of IgG and surrogate virus neutralising test (sVNT) levels (Wuhan-Hu-1 and Omicron BA.1) were compared over 12 months. SARS-CoV-2 infections, and adverse and serious adverse events (SAEs), were documented. CLINICALTRIALS: gov Identifier: NCT05265065. RESULTS: Of 601 participants randomised between May 27th and September 30th, 2022, 2 (0.3 %) were lost to follow-up and 19 (3.2 %) withdrew by 12 months. IgG levels declined from 28 days to six months, stabilising thereafter. At 12 months, IgG levels were lower in the fractional compared with the standard arm for ChAdOx1-S primed participants (GMR 0.78 [95 % CI 0.63-0.96], p = 0.017). At six and 12 months, the median sVNT inhibition percentages were comparable by study arm and priming strata. Documented SARS-CoV-2 infections occurred in 25 participants (fractional dose arm n = 12; standard dose arm n = 13). From 28 days, 228 undocumented infections (≥ 1.2-fold IgG increase) occurred (fractional arm n = 112; standard arm n = 116). SAEs (n = 41) were balanced between arms, with no severe vaccine-related AEs or SAEs reported. CONCLUSIONS: 15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity.
    Scopus© Citations 3
  • Some of the metrics are blocked by your 
    Item type:Publication,
    A Randomized Trial of Vitamin D Supplementation and COVID-19 Clinical Outcomes and Long COVID: The Vitamin D for COVID-19 Trial
    (2026-04) ;
    Cook, Kaitlyn A
    ;
    Khudyakov, Polyna
    ;
    ;
    BACKGROUND: Data from randomized controlled trials of vitamin D3 supplementation in modifying the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are sparse. OBJECTIVES: We evaluated the effect of vitamin D3 supplementation on healthcare utilization and other clinical outcomes among adults with coronavirus disease 2019 (COVID-19) and their close contacts. METHODS: We conducted a parallel 2-group randomized controlled double-blinded trial targeting free-living adults in the United States and Mongolia. Index participants with newly diagnosed COVID-19 were cluster-randomized with up to one of their cohabiting contacts either to an oral vitamin D3 loading dose of 9600 IU/d for 2 d followed by 3200 IU/d for 4 wk or to placebo. Participants completed weekly questionnaires on healthcare utilization, disease severity, and long COVID (index participants) or new SARS-CoV-2 infection (household contacts). The primary outcome was ≥1 healthcare visits (including hospitalization) or death within 4 wk among the index participants. RESULTS: Index participants (n = 1747) were a median of 38.0 y old (IQR: 31.1-47.0), 65.6% female/other sex, 4.2% Black non-Hispanic, 4.8% Hispanic/Latinx, 43.2% Asian, 44.3% non-Hispanic White, and 44.9% vitamin D deficient or insufficient (25-hydroxyvitamin D3 <20 ng/mL). Baseline characteristics for the household contacts (n = 277) were similar. The 4-wk cumulative incidence of healthcare utilization in index participants did not significantly differ between the vitamin D3 (n = 863) and placebo (n = 884) groups [cumulative incidences, 0.28 compared with 0.29; odds ratio (OR), 0.97; 95% confidence interval (CI): 0.75, 1.24]. Similar nonsignificant results were observed for the prespecified secondary treatment and prevention outcomes, though per-protocol analyses showed a nonsignificant trend toward benefit of vitamin D3 on the prevalence of long COVID at 8 wk (OR, 0.78; 95% CI: 0.59, 1.03). No safety concerns were identified. CONCLUSIONS: Among adults with newly diagnosed SARS-CoV-2 infections, vitamin D3 supplementation did not significantly change the 4-wk cumulative incidence of healthcare utilization or COVID-19-related outcomes compared with placebo. Promising results for long COVID warrant further study. This study was registered at clinicaltrials.gov as NCT04536298. First registered on 1 September, 2020.
    Scopus© Citations 2
  • Some of the metrics are blocked by your 
    Item type:Publication,
    One-year antibody kinetics and effectiveness of a BNT162b2 booster after four primary COVID-19 vaccination regimens in Mongolia
    (2026-09)
    Bazarjav, Purevbat
    ;
    Erdene-Ochir, Tseyenkhorloo
    ;
    Sandagdorj, Ankhbayar
    ;
    Enkhtuvshin, Altansukh
    ;
    Enkhbayar, Purevjargal
    BACKGROUND: Waning immunity after primary COVID-19 vaccination and the widespread use of heterogeneous vaccine platforms have created uncertainty regarding the durability of protection following booster vaccination. Mongolia implemented a mixed-platform vaccination program and deployed BNT162b2 as a booster. We evaluated the immunogenicity, effectiveness, and safety of a BNT162b2 booster following four primary vaccination regimens with 12 months follow-up. METHODS: In this prospective observational study in Ulaanbaatar, Mongolia, adults (≥18 years) who had completed a homologous two-dose primary series with BBIBP-CorV, ChAdOx1 nCoV-19, Gam-COVID-Vac, or BNT162b2 received a BNT162b2 booster a median of 189 days (IQR 186-215) after the second dose and were grouped according to their primary vaccination regimen. Humoral immune responses (anti-SARS-CoV-2 N/S1-RBD IgG, S-RBD IgG, and neutralizing antibodies) were measured at baseline and at multiple time points up to 12 months after booster vaccination. Reactogenicity was monitored for 28 days. SARS-CoV-2 infection was ascertained by a positive antigen/lateral-flow test and/or RT-PCR. VE was estimated for prespecified follow-up intervals by comparing the risk of SARS-CoV-2 infection in each boosted group with that in an unvaccinated comparison group. FINDINGS: Among 311 participants (mean age 41.88 years [SD 13.64]; 175 [56.27%] women and 136 [43.73%] men), antibody responses peaked at day 14 and declined through day 365 in all groups. At day 14, total antibody concentrations were highest in BNT + BNT (385.03 U/mL) and lowest in Gam + BNT (341.74 U/mL). S-RBD IgG at day 14 was highest in BNT + BNT (967.0 ng/mL) and lowest in BBIBP+BNT (863.70 ng/mL). Neutralizing antibodies at day 14 were highest in BNT + BNT (368.13 AU/mL) and BBIBP+BNT (336.70 AU/mL). During follow-up, 64 participants acquired SARS-CoV-2 infection and 15 (23.44%) were admitted to hospital. Reactogenicity was predominantly mild-to-moderate, and laboratory parameters were generally within acceptable ranges. Vaccine effectiveness declined from 1 month to 12 months: BBIBP+BNT 90.54% (95% CI 59.71-97.78) to 71.17% (39.66-86.23); ChAd+BNT 84.97% (49.75-95.51) to 52.59% (8.61-75.41); Gam + BNT 89.68% (23.95-98.60) to 63.84% (15.10-84.60); BNT + BNT 91.89% (40.06-98.90) to 72.29% (34.37-88.30). INTERPRETATION: A BNT162b2 booster following diverse primary COVID-19 vaccination regimens induced strong humoral responses that declined over 12 months and showed an acceptable reactogenicity profile. VE against SARS-CoV-2 infection was highest soon after boosting and lower later in follow-up. Although antibody levels and VE showed similar temporal patterns, these findings should be interpreted as complementary outcomes rather than evidence of a direct causal relationship or a formal immunological correlate of protection.